1. Home
  2. BCG vs LITS Comparison

BCG vs LITS Comparison

Compare BCG & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BCG

Binah Capital Group Inc.

HOLD

Current Price

$1.54

Market Cap

26.2M

Sector

N/A

ML Signal

HOLD

LITS

Lite Strategy Inc.

HOLD

Current Price

$0.74

Market Cap

25.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCG
LITS
Founded
2016
2000
Country
United States
United States
Employees
150
4
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.2M
25.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BCG
LITS
Price
$1.54
$0.74
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
32.2K
532.6K
Earning Date
05-14-2026
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$56.15
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.36
$0.69
52 Week High
$3.44
$3.03

Technical Indicators

Market Signals
Indicator
BCG
LITS
Relative Strength Index (RSI) 37.55 27.30
Support Level $1.52 N/A
Resistance Level $1.84 $1.23
Average True Range (ATR) 0.09 0.08
MACD 0.01 -0.02
Stochastic Oscillator 17.94 15.24

Price Performance

Historical Comparison
BCG
LITS

About BCG Binah Capital Group Inc.

Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.

About LITS Lite Strategy Inc.

Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.

Share on Social Networks: